X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (240) 240
oncology (232) 232
humans (209) 209
egfr-tkis (190) 190
tyrosine kinase inhibitors (162) 162
gefitinib (148) 148
tkis (140) 140
chemotherapy (127) 127
mutation (124) 124
lung cancer (117) 117
erlotinib (106) 106
nsclc (103) 103
lung neoplasms - drug therapy (98) 98
cancer (97) 97
open-label (97) 97
respiratory tract diseases (94) 94
protein kinase inhibitors - therapeutic use (93) 93
tyrosine (93) 93
epidermal growth factor (92) 92
female (92) 92
carcinoma, non-small-cell lung - drug therapy (91) 91
egfr (87) 87
male (87) 87
lung cancer, non-small cell (85) 85
acquired-resistance (79) 79
middle aged (76) 76
care and treatment (74) 74
lung neoplasms - genetics (69) 69
1st-line treatment (68) 68
aged (66) 66
non-small cell lung cancer (64) 64
carcinoma, non-small-cell lung - genetics (62) 62
antineoplastic agents - therapeutic use (60) 60
cell lung-cancer (60) 60
growth-factor receptor (60) 60
receptor, epidermal growth factor - antagonists & inhibitors (59) 59
adenocarcinoma (58) 58
metastasis (57) 57
neoplasms. tumors. oncology. including cancer and carcinogens (56) 56
respiratory system (56) 56
review (55) 55
adult (54) 54
kinases (53) 53
lung neoplasms - pathology (52) 52
resistance (52) 52
receptor, epidermal growth factor - genetics (51) 51
treatment outcome (49) 49
mutations (47) 47
analysis (45) 45
cancer therapies (45) 45
genetic aspects (44) 44
carcinoma, non-small-cell lung - pathology (43) 43
prognosis (43) 43
therapy (43) 43
cell biology (42) 42
lung neoplasms (40) 40
protein kinase inhibitors - pharmacology (39) 39
aged, 80 and over (38) 38
animals (38) 38
egfr tkis (38) 38
meta-analysis (38) 38
research (37) 37
egfr mutation (36) 36
cell line, tumor (35) 35
epidermal growth factor receptor (35) 35
medicine & public health (35) 35
pharmacology & pharmacy (35) 35
phenols (34) 34
survival (34) 34
non-small cell lung carcinoma (32) 32
non-small-cell lung cancer (32) 32
tyrosine kinase inhibitor (32) 32
disease-free survival (31) 31
hematology (31) 31
protein-tyrosine kinase (31) 31
development and progression (30) 30
drug resistance (30) 30
patients (30) 30
quinazolines - therapeutic use (30) 30
targeted therapy (30) 30
chronic myeloid leukemia (29) 29
expression (29) 29
apoptosis (28) 28
retrospective studies (28) 28
drug resistance, neoplasm (27) 27
egfr mutations (27) 27
health aspects (27) 27
lung adenocarcinoma (27) 27
medical prognosis (27) 27
protein kinase inhibitors - adverse effects (27) 27
double-blind (26) 26
tumors (26) 26
afatinib (25) 25
antineoplastic agents - pharmacology (25) 25
efficacy (25) 25
erbb receptors - genetics (25) 25
original (25) 25
phase-iii (24) 24
protein-tyrosine kinases - antagonists & inhibitors (24) 24
epidermal growth factor receptors (23) 23
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (533) 533
Chinese (27) 27
French (3) 3
Korean (2) 2
Hungarian (1) 1
Japanese (1) 1
Polish (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Acta Pharmaceutica Sinica B, ISSN 2211-3835, 09/2015, Volume 5, Issue 5, pp. 390 - 401
Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors... 
Resistance | Mechanisms | TKIs | EGFR | TARGETED THERAPY | ACQUIRED-RESISTANCE | T790M MUTATION | GEFITINIB RESISTANCE | CELL LUNG-CANCER | EPITHELIAL-MESENCHYMAL TRANSITION | GROWTH-FACTOR RECEPTOR | ERLOTINIB RESISTANCE | PHARMACOLOGY & PHARMACY | INTEGRIN BETA1 | TUMOR-GROWTH | ALK, anaplastic lymphoma kinase | BH3, BCL2-homology domain 3 | PDGFRs, platelet-derived growth factor receptors | lymphoma-2 | PDGFs, platelet-derived growth factors | PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase,catalytic subunit alpha | VEGFR, vascular endothelial growth factor receptor | RAF, rapidly accelerated fibrosarcoma | FGFs, fibroblast growth factors | BCL-2, B-cell CLL | IGFBPs, IGF-binding proteins | ERK1 | BIM, BCL2-like 11 | ABCC10, ATP binding cassette, sub-family C, member 10 | ABCC1, ATP binding cassette, sub-family C, member 1 | VEGF, vascular endothelial growth factor | TKs, tyrosine kinases | HER, human epidermal receptor | MEK, mitogen-activated protein kinase | EGFR, epidermal growth factor receptor | BRAF, v-RAF murine sarcoma viral oncogene homolog B1 | AXL, Anexelekto | AKT, protein kinase B | IL, interleukin | TKIs, tyrosine kinase inhibitors | RAS, rat sarcoma | RTK, tyrosine kinase receptor | MAPK, mitogen-activated protein kinase | FGFRs, fibroblast growth factor receptors | SOCS3, suppressor of cytokine signaling 3 | EMT, epithelial mesenchymal transition | IGF, insulin growth factor | Review | 2, extracellular signal-regulated kinases | EML4, echinoderm microtubule-associated protein-like 4 | ABCG2, ATP binding cassette, sub-family G, member 2 | ABCB1, ATP binding cassette, sub-family B, member 1 | BCL2L11 | IL-6R, IL-6 receptor | IGF-1R, IGF-1 receptor | SF, scatter factor | PI3K, phosphatidylinositol-3-kinase | CML, chronic myelogenous leukemia | EGFR-TKIs, epidermal growth factor receptor tyrosine kinase inhibitors | JAK, janus kinase | NSCLC, non-small cell lung cancer | ABC, ATP binding cassette | GAS6, growth-arrest-specific protein 6 | STAT, signal transducers and activators of transcription | EGFRvIII, EGFR variant III | CRKL, Crk-like protein | HGF, hepatocyte growth factor | PTEN, phosphatase and tensin homolog
Journal Article
Expert Opinion on Investigational Drugs, ISSN 1354-3784, 10/2019, Volume 28, Issue 10, pp. 903 - 916
Introduction: Fibroblast growth factor receptor 2 (FGFR2) is a highly conserved transmembrane tyrosine kinase receptor. FGFR2 dysregulation occurs in numerous... 
solid tumor | Fibroblast growth factor receptor 2 (FGFR2) | multi-target tyrosine kinase inhibitors (TKIs) | antibody | FGFR-target TKIs
Journal Article
Oncotarget, ISSN 1949-2553, 01/2019, Volume 10, Issue 2, pp. 84 - 85
Journal Article
Translational Lung Cancer Research, ISSN 2218-6751, 2012, Volume 1, Issue 4, pp. 287 - 288
Journal Article
Translational Lung Cancer Research, ISSN 2218-6751, 2013, Volume 2, Issue 1, pp. 58 - 61
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 09/2019, Volume 19, pp. S66 - S70
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2018, Volume 36, Issue 26, pp. 2702 - 2709
PurposeIn patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC), there is an unmet need for... 
GEFITINIB | MULTICENTER | PERMEABILITY | ONCOLOGY | METASTASES | ACQUIRED-RESISTANCE | EGFR-TKIS | TYROSINE KINASE INHIBITOR | OPEN-LABEL | BLOOD-BRAIN-BARRIER
Journal Article
Translational Lung Cancer Research, ISSN 2218-6751, 2012, Volume 1, Issue 4, pp. 280 - 282
Journal Article
Translational Lung Cancer Research, ISSN 2218-6751, 2013, Volume 2, Issue 1, pp. 62 - 63
Journal Article
Translational Lung Cancer Research, ISSN 2218-6751, 2013, Volume 2, Issue 1, pp. 55 - 57
Journal Article
Translational Lung Cancer Research, ISSN 2218-6751, 2013, Volume 2, Issue 1, pp. 50 - 54
Journal Article
Bioorganic and Medicinal Chemistry Letters, ISSN 0960-894X, 2016, Volume 26, Issue 24, pp. 5985 - 5988
EGFR (epidermal growth factor receptor) targeted therapy has shown great success in clinical comparing with chemotherapy in EGFR mutation NSCLCs. Such as,... 
Imaging | TKIs | PET/CT | F-IRS | EGFR
Journal Article
Translational Lung Cancer Research, ISSN 2218-6751, 2012, Volume 1, Issue 4, pp. 283 - 286
Journal Article
Oncotarget, ISSN 1949-2553, 08/2019, Volume 10, Issue 50, p. 5168
Among challenges of targeted therapies is the activation of alternative pro-survival signaling pathways in cancer cells, resulting in an acquired drug... 
Journal Article
by Wang J and Wang B and Chu H and Yao Y
OncoTargets and Therapy, ISSN 1178-6930, 06/2016, Volume 2016, Issue Issue 1, pp. 3711 - 3726
Jun Wang, Baocheng Wang, Huili Chu, Yunfeng Yao Department of Oncology, General Hospital, Jinan Command of the People's Liberation Army, Jinan, People's... 
EGFR TKIs | NSCLC | intrinsic resistance
Journal Article
Oncotarget, ISSN 1949-2553, 2018, Volume 9, Issue 10, pp. 9480 - 9488
Two anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (-TKIs) have been approved for the treatment of patients with ALK-rearranged (ALK-positive)... 
ALK TKIs | Liver toxicity | Lung cancer | Meta-analysis
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.